Erratum: HIV prevention in clinical care settings: 2014 Recommendations of the international antiviral society-USA panel (Journal of the American Medical Association (2014) 312, 4 (390-409) DOI:10.1001/jama.2014.7999);HIV prevention in clinical care settings: 2014 Recommendations of the International Antiviral Society-USA Panel

JAMA

Volumn 312, Issue 4, 2014, Pages 390-409

  Marrazzo, Jeanne M ^a   Del Rio, Carlos ^b   Holtgrave, David R ^c   Cohen, Myron S ^d   Kalichman, Seth C ^e   Mayer, Kenneth H ^f   Montaner, Julio S G ^g   Wheeler, Darrell P ^h   Grant, Robert M ⁱ   Grinsztejn, Beatriz ^j   Kumarasamy, N ^k   Shoptaw, Steven ^l   Walensky, Rochelle P ^m   Dabis, Francois ⁿ   Sugarman, Jeremy ^o   Benson, Constance A ^p  

^a UNIVERSITY OF WASHINGTON   (United States)

^b EMORY UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Funda??o Oswaldo Cruz   (Brazil)

^k YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; CIRCUMCISION; HEALTH CARE PRACTICE; HEALTH PROGRAM; HIGH RISK POPULATION; HIV TEST; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INTEGRATION; PATIENT COMPLIANCE; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROPHYLAXIS; REPEAT PROCEDURE; REVIEW; RISK REDUCTION; SERODIAGNOSIS; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COUNSELING; FEMALE; HARM REDUCTION; HIV INFECTIONS; HIV-1; HUMANS; MALE; POST-EXPOSURE PROPHYLAXIS; RISK; RISK REDUCTION BEHAVIOR; SEXUALLY TRANSMITTED DISEASES;

EID: 84904582241     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.9685     Document Type: Erratum

References (250)

1. Prejean J, Song R, Hernandez A, et al HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
2. Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much to do. Nat Immunol. 2013;14(11):1104-1107.
3. American Academy of Pediatrics Task Force on Circumcision. Circumcision policy statement. Pediatrics. 2012;130(3):585-586.
4. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121(9):1193-1254.
5. Centers for Disease Control and Prevention (CDC). Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data-United States and 6 Dependent Areas-2011. CDC website. http://www.cdc.gov/ hiv/pdf/2011-Monitoring-HIV-Indicators-HSSR-FINAL.pdf. Accessed May 23, 2014.
6. Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632-1636.
7. Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav. 2009;13(6):1054-1060.
8. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012;26(7):893-896.
9. Branson BM, Handsfield HH, Lampe MA, et al Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17, quiz CE1-CE4.
10. Moyer VA; U.S. Preventive Services Task Force&z.ast;. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;159(1):51-60.
11. Food and Drug Administration (FDA). Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. FDA website. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/ LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM080466. Accessed May 23, 2014.
12. Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. Clin Infect Dis. 2013;57(5):712-718.
13. Paltiel AD, Walensky RP. Home HIV testing: good news but not a game changer. Ann Intern Med. 2012;157(10):744-746.
14. Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis. 2012;205(4):521-524.
15. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013;62(24):489-494http://www.cdc. gov/mmwr/preview/mmwrhtml/mm6224a2.htm?s-cid=mm6224a2-e. Accessed May 23, 2014.
16. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010 [published correction appears in MMWR Recomm Rep. 2011;60(1):18]. MMWR Recomm Rep. 2010;59(RR-12):1-110.
17. Sullivan PS, White D, Rosenberg ES, et al. Safety and acceptability of couples HIV testing and counseling for US men who have sex with men: a randomized prevention study. J Int Assoc Provid AIDS Care. 2014;13(2):135-144.
18. World Health Organization (WHO). Guidance on Couples HIV Testing And Counselling-Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. WHO website. http://apps.who.int/iris/bitstream/10665/44646/1/9789241501972-eng.pdf. Accessed May 23, 2014.
19. Centers for Disease Control and Prevention (CDC). State HIV Laws. CDC website. http://www.cdc.gov/hiv/policies/law/states/index.html. Accessed May 23, 2014.
20. Kamb ML, Fishbein M, Douglas JM Jr, et al Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA. 1998;280(13):1161-1167. (Pubitemid 28457806)
21. Bolu OO, Lindsey C, Kamb ML, et al Project RESPECT Study Group. Is HIV/sexually transmitted disease prevention counseling effective among vulnerable populations?: a subset analysis of data collected for a randomized, controlled trial evaluating counseling efficacy (Project RESPECT). Sex Transm Dis. 2004;31(8):469-474. (Pubitemid 38989643)
22. Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: ameta-analytic review of published research, 1985-1997. Am J Public Health. 1999;89(9):1397-1405. (Pubitemid 29404565)
23. Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160-1167.
24. Metcalf CA, Douglas JM Jr, Malotte CK, et al; RESPECT-2 Study Group. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130-138.
25. Holtgrave D, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. Clin Infect Dis. 2007;45(suppl 4):S240-S243. (Pubitemid 351417223)
26. Metcalf CA, Malotte CK, Douglas JM Jr, et al; RESPECT-2 Study Group. Efficacy of a booster counseling session 6 months after HIV testing and counseling: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):123-129.
27. Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013;310(16):1701-1710.
28. Semaan S, Neumann MS, Hutchins K, D'Anna LH, Kamb ML; Project RESPECT Study Group. Brief counseling for reducing sexual risk and bacterial STIs among drug users - results from project RESPECT. Drug Alcohol Depend. 2010;106(1):7-15.
29. Dilley JW, Woods WJ, Sabatino J, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. J Acquir Immune Defic Syndr. 2002;30(2):177-186. (Pubitemid 34664414)
30. Dilley JW, Woods WJ, Loeb L, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. J Acquir Immune Defic Syndr. 2007;44(5):569-577. (Pubitemid 46594902)
31. Coffin PO, Santos GM, Colfax G, et al. Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial. AIDS Behav. 2014;18(7):1390-1400.
32. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570-585. (Pubitemid 40204670)
33. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586-595. (Pubitemid 40204671)
34. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797-806. (Pubitemid 351650333)
35. Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention for substance-using HIV-positive young people: telephone and in-person delivery. J Acquir Immune Defic Syndr. 2004;37(suppl 2):S68-S77.
36. Lightfoot M, Rotheram-Borus MJ, Tevendale H. An HIV-preventive intervention for youth living with HIV. Behav Modif. 2007;31(3):345-363.
37. El-Bassel N, Jemmott JB, Landis JR, et al NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. National Institute of Mental Health Multisite Eban HIV/STD Prevention Intervention for African American HIV Serodiscordant Couples: a cluster randomized trial. Arch Intern Med. 2010;170(17):1594-1601.
38. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr. 2007;44(2):213-221.
39. Kalichman SC, Rompa D, Cage M, et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med. 2001;21(2):84-92. (Pubitemid 32660421)
40. Kalichman SC, Cherry C, Kalichman MO, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health. 2011;101(3):531-538.
41. Sikkema KJ, Wilson PA, Hansen NB, et al. Effects of a coping intervention on transmission risk behavior among people living with HIV/AIDS and a history of childhood sexual abuse. J Acquir Immune Defic Syndr. 2008;47(4):506-513. (Pubitemid 351366962)
42. Gilbert P, Ciccarone D, Gansky SA, et al. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One. 2008;3(4):e1988.
43. Wolitski RJ, Gómez CA, Parsons JT. Effects of a peer-led behavioral intervention to reduce HIV transmission and promote serostatus disclosure among HIV-seropositive gay and bisexual men. AIDS. 2005;19(suppl 1):S99-S109.
44. McKirnan DJ, Tolou-Shams M, Courtenay-Quirk C. The Treatment Advocacy Program: a randomized controlled trial of a peer-led safer sex intervention for HIV-infected men who have sex with men. J Consult Clin Psychol. 2010;78(6):952-963.
45. Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program. J Acquir Immune Defic Syndr. 2004;37(suppl 2):S58-S67.
46. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44-52. (Pubitemid 41786018)
47. Richardson JL, Milam J, McCutchan A, et al. Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS. 2004;18(8):1179-1186. (Pubitemid 38738517)
48. Golin CE, Earp JA, Grodensky CA, et al. Longitudinal effects of SafeTalk, a motivational interviewing-based program to improve safer sex practices among people living with HIV/AIDS. AIDS Behav. 2012;16(5):1182-1191.
49. Rotheram-Borus MJ, Lee MB, Murphy DA, et al Teens Linked to Care Consortium. Efficacy of a preventive intervention for youths living with HIV. Am J Public Health. 2001;91(3):400-405. (Pubitemid 32179453)
50. Centers for Disease Control and Prevention (CDC). Listing of all risk reduction interventions, by characteristic. http://www.cdc.gov/hiv/prevention/ research/compendium/rr/characteristics.html. Accessed on May 23, 2014.
51. Crepaz N, Tungol-Ashmon MV, Higa DH, et al. A systematic review of interventions for reducing HIV risk behaviors among people living with HIV in the United States, 1988-2012. AIDS. 2014;28(5):633-656.
52. Crosby R, DiClemente RJ, Charnigo R, Snow G, Troutman A. A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health. 2009;99(suppl 1):S96-S103.
53. Jemmott LS, Jemmott JB III, O'Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. Am J Public Health. 2007;97(6):1034-1040. (Pubitemid 351181925)
54. James NJ, Gillies PA, Bignell CJ. Evaluation of a randomized controlled trial of HIV and sexually transmitted disease prevention in a genitourinary medicine clinic setting. AIDS. 1998;12(10):1235-1242. (Pubitemid 28302426)
55. Patterson TL, Mausbach B, Lozada R, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health. 2008;98(11):2051-2057.
56. Warner L, Klausner JD, Rietmeijer CA, et al Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med. 2008;5(6):e135.
57. Shrier LA, Ancheta R, Goodman E, Chiou VM, Lyden MR, Emans SJ. Randomized controlled trial of a safer sex intervention for high-risk adolescent girls. Arch Pediatr Adolesc Med. 2001;155(1):73-79. (Pubitemid 32047393)
58. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397-1404.
59. Donnell D, Baeten JM, Kiarie J, et al Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-2098.
60. Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55(2):232-238.
61. Birungi J, Wang H, Ngolobe MH, et al. Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load monitoring in Uganda. Presented at: 19th International AIDS Conference (IAS); July 22-27, 2012;Washington, DC.
62. Montaner J, Hogg R. Implications of the Henan Province report on the treatment as prevention debate. J Acquir Immune Defic Syndr. 2011;56(3):e101-e102, author reply e101-e102.
63. Rodger A, Bruun T, Cambiano V, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study [Abstract 153LB]. Presented at: 2014 Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
64. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
65. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281-290.
66. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532-539.
67. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966-971.
68. Montaner JS. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission-The "HIV Treatment as Prevention" experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872.
69. US Department of State. PEPFAR Blueprint: Creating an AIDS-Free Generation. Pepfar website. http://www.pepfar.gov/documents/organization/201386. pdf. Accessed May 23, 2014.
70. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO website. http://apps.who.int/iris/bitstream/ 10665/85321/1/9789241505727-eng.pdf. Accessed on May 23, 2013.
71. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
72. US Department of Health and Human Services and Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: March 27, 2012. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed May 23, 2014.
73. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778-789.
74. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013; 369(18):1715-1725.
75. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8(2):e55312.
76. Brenner BG, Roger M, Stephens D, et al Montreal PHI Cohort Study Group. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis. 2011;204(7):1115-1119.
77. Chibo D, Kaye M, Birch C. HIV transmissions during seroconversion contribute significantly to new infections in men who have sex with men in Australia. AIDS Res Hum Retroviruses. 2012;28(5):460-464.
78. Miller WC, Leone PA, McCoy S, Nguyen TQ, Williams DE, Pilcher CD. Targeted testing for acute HIV infection in North Carolina. AIDS. 2009;23(7):835-843.
79. Weintrob AC, Giner J, Menezes P, et al. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med. 2003;163(17):2097-2100. (Pubitemid 37151254)
80. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet. 2011;378(9787):256- 268.
81. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary - will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9(7):e1001232.
82. Pettifor A, MacPhail C, Corneli A, et al NIAID Center for HIV/AIDS Vaccine Immunology. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav. 2011;15(6):1243-1250.
83. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-230.
84. Grinsztejn B, Hosseinipour MC, Ribaudo H, et al Effects of early versus delayed initation of antiretroviral therapy on HIV clinical outcomes: results from the phase 3 HPTN 052 randomized controlled trial. Lancet Infect Dis. 2014;14(4):281-290.
85. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012;109(24):9523-9528.
86. Pati R, Lahuerta M, Elul B, et al Identifying Optimal Models of HIV Care in Mozambique Study Group. Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique. J Int AIDS Soc. 2013;16:18490.
87. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-833, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.
88. Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients - a systematic review. HIV Med. 2013;14(10):583-595.
89. Murphy DA, Marelich WD, Rappaport NB, Hoffman D, Farthing C. Results of an antiretroviral adherence intervention: STAR (Staying Healthy: Taking Antiretrovirals Regularly). J Int Assoc Physicians AIDS Care (Chic). 2007;6(2):113-124.
90. Simoni JM, Wiebe JS, Sauceda JA, et al. A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: the Nuevo Día study. AIDS Behav. 2013;17(8):2816-2829.
91. Simoni JM, Chen WT, Huh D, et al. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. AIDS Behav. 2011;15(5):919-929.
92. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28(1):1-10.
93. Parsons JT, Rosof E, Punzalan JC, Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDS. 2005;19(1):31-39. (Pubitemid 40170841)
94. Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. 2012;24(5):583-592.
95. Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42(1):42-51. (Pubitemid 43947945)
96. Gross R, Bellamy SL, Chapman J, et al. Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med. 2013;173(4):300-306.
97. Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med. 2011;41(1):83-91.
98. Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 2007;26(4):488-495. (Pubitemid 47445006)
99. Horvath KJ, Oakes JM, Rosser BR, et al. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. AIDS Behav. 2013;17(6):2031-2044.
100. Reznick OG, McCartney K, Gregorich SE, Zack B, Feaster DJ. An ecosystem-based intervention to reduce HIV transmission risk and increase medication adherence among inmates being released to the community. J Correct Health Care. 2013;19(3):178-193.
101. Letourneau EJ, Ellis DA, Naar-King S, Chapman JE, Cunningham PB, Fowler S. Multisystemic therapy for poorly adherent youth with HIV: results from a pilot randomized controlled trial. AIDS Care. 2013;25(4):507-514.
102. Himelhoch S, Medoff D, Maxfield J, et al. Telephone based cognitive behavioral therapy targeting major depression among urban dwelling, low income people living with HIV/AIDS: results of a randomized controlled trial. AIDS Behav. 2013;17(8):2756-2764.
103. Kalichman SC, Cherry C, Kalichman MO, et al. Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacy. J Acquir Immune Defic Syndr. 2013;63(1):42-50.
104. Kalichman SC, Cherry J, Cain D. Nurse-delivered antiretroviral treatment adherence intervention for people with low literacy skills and living with HIV/AIDS. J Assoc Nurses AIDS Care. 2005;16(5):3-15. (Pubitemid 41475426)
105. Reynolds NR, Testa MA, Su M, et al AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008;47(1):62-68. (Pubitemid 351619370)
106. Kalichman SC, Kalichman MO, Cherry C, et al. Brief behavioral self-regulation counseling for HIV treatment adherence delivered by cell phone: an initial test of concept trial. AIDS Patient Care STDS. 2011;25(5):303-310.
107. Wohl AR, Garland WH, Wu J, et al. A youth-focused case management intervention to engage and retain young gay men of color in HIV care. AIDS Care. 2011;23(8):988-997.
108. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287-312.
109. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113(2-3):192-199.
110. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: ameta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr. 2011;58(5):489-498.
111. Scott-Sheldon LA, Fielder RL, Carey MP. Sexual risk reduction interventions for patients attending sexually transmitted disease clinics in the United States: ameta-analytic review, 1986 to early 2009. Ann Behav Med. 2010;40(2):191-204.
112. Johnson BT, Scott-Sheldon LA, Smoak ND, Lacroix JM, Anderson JR, Carey MP. Behavioral interventions for African Americans to reduce sexual risk of HIV: ameta-analysis of randomized controlled trials. J Acquir Immune Defic Syndr. 2009;51(4):492-501.
113. Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. AIDS Behav. 2008;12(3):335-353. (Pubitemid 351667238)
114. Herbst JH, Sherba RT, Crepaz N, et al HIV/AIDS Prevention Research Synthesis Team. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. J Acquir Immune Defic Syndr. 2005;39(2):228-241. (Pubitemid 40741123)
115. Soorapanth S, Chick SE. Cost-utility analysis of behavioral interventions for HIV-infected persons to reduce HIV transmission in the US. In: Johansson S, Jain S, Montayo-Torres J, Huga J, Yucesan E, eds. Proceedings of the 2010 Winter Simulation Conference. Baltimore, MD: 2013.
116. Lee MB, Leibowitz A, Rotheram-Borus MJ. Cost-effectiveness of a behavioral intervention for seropositive youth. AIDS Educ Prev. 2005;17(2):105-118. (Pubitemid 40604907)
117. Mizuno Y, Zhu J, Crepaz N, et al. Receipt of HIV/sexually transmitted disease prevention counseling by HIV-infected adults receiving medical care in the United States. AIDS. 2014;28(3):407-415.
118. Naar-King S, Parsons JT, Johnson AM. Motivational interviewing targeting risk reduction for people with HIV: a systematic review. Curr HIV/AIDS Rep. 2012;9(4):335-343.
119. Golin CE, Davis RA, Przybyla SM, et al. SafeTalk, a multicomponent, motivational interviewing-based, safer sex counseling program for people living with HIV/AIDS: a qualitative assessment of patients' views. AIDS Patient Care STDS. 2010;24(4):237-245.
120. Kalichman SC, Cain D, Weinhardt L, et al. Experimental components analysis of brief theory-based HIV/AIDS risk-reduction counseling for sexually transmitted infection patients. Health Psychol. 2005;24(2):198-208. (Pubitemid 40365682)
121. World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS. (UNAIDS). Guidance for HIV Testing and Counselling and Care for Adolescents Living With HIV. http://apps.who.int/iris/bitstream/10665/94334/1/ 9789241506168-eng.pdf. Accessed May 23, 2014.
122. Napper LE, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavior self-report reliability at different recall periods. AIDS Behav. 2010;14(1):152-161.
123. Schroder KE, Carey MP, Vanable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med. 2003;26(2):104-123. (Pubitemid 37271597)
124. National Network of STDHIV Prevention Training Centers. Ask, screen, intervene: incorporating HIV prevention into the medical care of persons living with HIV. http://nnptc.org/resources/asi-provider-card/. Accessed May 23, 2014.
125. Golden MR, Brewer DD, Kurth A, Holmes KK, Handsfield HH. Importance of sex partner HIV status in HIV risk assessment among men who have sex with men. J Acquir Immune Defic Syndr. 2004;36(2):734-742. (Pubitemid 38685968)
126. Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis. 2013;57(8):1203-1209.
127. Blish CA, McClelland RS, Richardson BA, et al. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. J Acquir Immune Defic Syndr. 2012;61(4):436-440.
128. Wagner GA, Pacold ME, Kosakovsky Pond SL, et al. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis. 2014;209(7):1032-1038.
129. Patton ME, Su JR, Nelson R, Weinstock H; Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis - United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014;63(18):402-406.
130. Centers for Disease Control and Prevention (CDC). HIV-Specific Criminal Laws. CDC website. http://www.cdc.gov/hiv/policies/law/states/exposure.html. Accessed May 23, 2014.
131. Taylor MM, Mickey T, Winscott M, James H, Kenney K, England B. Improving partner services by embedding disease intervention specialists in HIV-clinics. Sex Transm Dis. 2010;37(12):767-770.
132. Golden MR, Dombrowski JC, Wood RW, Fleming M, Harrington RD. A controlled study of the effectiveness of public health HIV partner notification services. AIDS. 2009;23(1):133-135.
133. The Well Project. Disclosure and HIV. The Well Project website. http://www.thewellproject.org/hiv-information/disclosure-and-hiv. Accessed May 23, 2014.
134. World Health Organization. UNODC, UNAIDS. Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment, and Care for Injecting Drug Users. Geneva, Switzerland: World Health Organization; 2012.
135. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268-284.
136. Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm
137. Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention.' Curr Opin HIV AIDS. 2012;7(4):332-338.
138. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907-913.
139. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health. 2011;88(3):545-555.
140. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;(2):CD004145.
141. Fu TC, Westergaard RP, Lau B, et al. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users. AIDS. 2012;26(18):2383-2391.
142. Marshall BD, Milloy MJ, Kerr T, Zhang R, Montaner JS, Wood E. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS. 2010;24(14):2271-2278.
143. United Nations Office on Drugs and Crime (UNODC). From Coercion to Cohesion: Treating Drug Dependence Through Health Care, Not Punishment [Discussion paper]. UNODC website. http://www.unodc.org/docs/treatment/Coercion- Ebook.pdf. Accessed May 23, 2014.
144. Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. 2008;85(3):309-322.
145. Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ. 2006;175(11):1399-1404. (Pubitemid 44876560)
146. Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One. 2008;3(10):e3351.
147. Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006;354(23):2512-2514. (Pubitemid 43855074)
148. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf). 2007;29(1):35-39.
149. Marshall BD, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Condom use among injection drug users accessing a supervised injecting facility. Sex Transm Infect. 2009;85(2):121-126.
150. Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13.
151. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777-786.
152. Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012;184(6):317-328.
153. Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168-1175.
154. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend. 2007;87(2-3):249-257. (Pubitemid 46215934)
155. Gardner LI, Metsch LR, Anderson-Mahoney P, et al Antiretroviral Treatment and Access Study Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423-431. (Pubitemid 40446189)
156. Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99-105.
157. Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005;25(3):321-329. (Pubitemid 40696281)
158. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39(5):557-561. (Pubitemid 41098470)
159. Bonolo PdeF, César CC, Acúrcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005;19(suppl 4):S5-S13.
160. Andersen M, Paliwoda J, Kaczynski R, et al. Integrating medical and substance abuse treatment for addicts living with HIV/AIDS: evidence-based nursing practice model. Am J Drug Alcohol Abuse. 2003;29(4):847-859. (Pubitemid 37549410)
161. Fuchs J, Durham M, McLellan-Lemal E, et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2007;46(3):362-368. (Pubitemid 350287367)
162. Blankenship KM, Bray SJ, Merson MH. Structural interventions in public health. AIDS. 2000;14(suppl 1):S11-S21.
163. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008;47(5):597-606. (Pubitemid 351442023)
164. Hightow-Weidman LB, Smith JC, Valera E, Matthews DD, Lyons P. Keeping them in "STYLE": finding, linking, and retaining young HIV-positive black and Latino men who have sex with men in care. AIDS Patient Care STDS. 2011;25(1):37-45.
165. Farber S, Tate J, Frank C, et al. A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS Behav. 2013;17(7):2293-2300.
166. Bocour A, Renaud TC, Udeagu C-CN, Shepard CW. HIV partner services are associated with timely linkage to HIV medical care. AIDS. 2013;27(18):2961-2963.
167. Mugavero MJ, Amico KR, Westfall AO, et al. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr. 2012;59(1):86-93.
168. Metsch LR, Pereyra M, Messinger S, et al Antiretroviral Treatment and Access Study (ARTAS) Study Group. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis. 2008;47(4):577-584.
169. Gardner LI, Giordano TP, Marks G, Wilson TE, et al Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in six U.S. HIV clinics [published online May 15, 2014]. Clin Infect Dis. doi:10.1093/cid/ciu357.
170. Naar-King S, Outlaw A, Green-Jones M, Wright K, Parsons JT. Motivational interviewing by peer outreach workers: a pilot randomized clinical trial to retain adolescents and young adults in HIV care. AIDS Care. 2009;21(7):868-873.
171. Hightow-Weidman LB, Jones K, Wohl AR, et al YMSM of Color SPNS Initiative Study Group. Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. AIDS Patient Care STDS. 2011;25(suppl 1):S31-S38.
172. Gardner LI, Marks G, Craw JA, et al Retention in Care Study Group. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012;55(8):1124-1134.
173. McCoy SI, Shiu K, Martz TE, et al. Improving the efficiency of HIV testing with peer recruitment, financial incentives, and the involvement of persons living with HIV infection. J Acquir Immune Defic Syndr. 2013;63(2):e56-e63.
174. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med. 2010;152(11):704-711.
175. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.
176. Gray RH, Kiwanuka N, Quinn TC, et al Rakai Project Team. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. AIDS. 2000;14(15):2371-2381.
177. Bailey RC, Muga R, Poulussen R, Abicht H. The acceptability of male circumcision to reduce HIV infections in Nyanza Province, Kenya. AIDS Care. 2002;14(1):27-40. (Pubitemid 34095164)
178. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
179. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
180. Choopanya K, Martin M, Suntharasamai P, et al Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.
181. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
182. Van Damme L, Corneli A, Ahmed K, et al FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
183. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract 26LB]. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2013; Atlanta, GA.
184. The White House Office of National AIDS Policy (ONAP). National HIV/AIDS Strategy for the United States. ONAP website. http://www.whitehouse.gov/ administration/eop/onap/. Accessed May 23, 2014.
185. Holtgrave DR. On the epidemiologic and economic importance of the National AIDS Strategy for the United States. J Acquir Immune Defic Syndr. 2010;55(2):139-142.
186. Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS strategy in the United States: a closing window for success? AIDS Behav. 2012;16(6):1365-1372.
187. Centers for Disease Control (CDC). High-impact HIV prevention CDC's approach to reducing HIV infections in the United States. CDC website. http://www.cdc.gov/hiv/policies/hip.html. Accessed May 23, 2014.
188. US Preventive Services Task Force (USPSTF). Behavioral counseling to prevent sexually transmitted infections. USPSTF website. http://www. uspreventiveservicestaskforce.org/uspstf08/sti/stirs.htm. Accessed May 23, 2014.
189. Eaton LA, Kalichman SC, Kenny DA, Harel O. A reanalysis of a behavioral intervention to prevent incident HIV infections: including indirect effects in modeling outcomes of Project EXPLORE. AIDS Care. 2013;25(7):805-811.
190. Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364(9428):41-50.
191. Eaton LA, Huedo-Medina TB, Kalichman SC, et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. Am J Public Health. 2012;102(11):e34-e44.
192. Holtgrave DR, Maulsby C, Wehrmeyer L, Hall HI. Behavioral factors in assessing impact of HIV treatment as prevention. AIDS Behav. 2012;16(5):1085-1091.
193. Holtgrave DR, Hall HI, Des Jarlais DC, Mizuno Y, Purcell DW. Estimating number of diagnosed persons living with HIV in the United States engaged in unprotected serodiscordant risk behavior with unsuppressed viral load. J Acquir Immune Defic Syndr. 2014;65(3):e125-e128.
194. Rotheram-Borus MJ, Murphy DA, Coleman C, Swendeman D. Counseling adolescents: designing interventions to target routines, relationships, roles and stages of adaptation. In: ChesneyMA, Antoni MH, eds. Innovative Approaches to Health Psychology: Prevention and Treatment Lessons From AIDS. Washington, DC: American Psychology Association; 2002:15-44.
195. Townsend L, Mathews C, Zembe Y. A systematic review of behavioral interventions to prevent HIV infection and transmission among heterosexual, adult men in low-and middle-income countries. Prev Sci. 2013;14(1):88-105.
196. Rotheram-Borus MJ, Swendeman D, Flannery D, Rice E, Adamson DM, Ingram B. Common factors in effective HIV prevention programs. AIDS Behav. 2009;13(3):399-408.
197. Centers for Disease Control and Prevention (CDC). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-2014: A Clinical Practice Guideline. CDC website. http://www.cdc.gov/hiv/pdf/guidelines/ PrEPguidelines2014.pdf. Accessed May 23, 2014.
198. Anderson PL, Glidden DV, Liu A, et al; iPrEx Study Team. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):ra125.
199. García-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):ra4.
200. Spreen W, Williams P, Margolis D, et al. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety and tolerability in healthy adults [Abstract WEAB0103]. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
201. Abdool Karim SS, Richardson BA, Ramjee G, et al; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5%PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957-966.
202. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806-815.
203. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541-550.
204. García-Lerma JG, Heneine W. Animal models of antiretroviral prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2012;7(6):505-513.
205. Cardo DM, Culver DH, Ciesielski CA, et al Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997; 337(21):1485-1490. (Pubitemid 27495773)
206. Kuhar DT, Henderson DK, Struble KA, et al US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis [published correction appears in Infect Control Hosp Epidemiol. 2013;34(11):1238]. Infect Control Hosp Epidemiol. 2013;34(9):875-892.
207. Smith DK, Grohskopf LA, Black RJ, et al U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005;54(RR-2):1-20.
208. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH; Praca Onze Study Team. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519-525. (Pubitemid 38420661)
209. Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS. 2009;23(9):1119-1126.
210. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009;361(18):1768-1775.
211. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72(5):4265-4273. (Pubitemid 28188732)
212. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47(4):494-499. (Pubitemid 351366963)
213. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354-359.
214. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39(3):395-401. (Pubitemid 39050489)
215. Diaz-Brito V, León A, Knobel H, et al; DATEMPEP study group. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2012;17(2):337-346.
216. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005;41(10):1507-1513. (Pubitemid 41579997)
217. Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis. 2007;7:16.
218. Auvert B, Taljaard D, Rech D, et al. Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. PLoS Med. 2013;10(9):e1001509.
219. Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294-1301.
220. Mehta SD, Moses S, Agot K, et al. The long term efficacy of medical male circumcision against HIV acquisition [published online July 3, 2013]. AIDS. doi:10.1097/01.aids.0000432444.30308.2d.
221. Tobian AA, Kong X, Wawer MJ, et al. Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. Lancet Infect Dis. 2011;11(8):604-612.
222. Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS. 2009;23(12):1589-1594.
223. Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet. 2009;374(9685):229-237.
224. Hallett TB, Alsallaq RA, Baeten JM, et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sex Transm Infect. 2011;87(2):88-93.
225. Mavhu W, Hatzold K, Laver SM, et al. Acceptability of early infant male circumcision as an HIV prevention intervention in Zimbabwe: a qualitative perspective. PLoS One. 2012;7(2):e32475.
226. Gebremedhin S. Assessment of the protective effect of male circumcisioin from HIV infection and sexually transmitted diseases: evidence from 18 demographic and health surveys in Sub-Saharan Africa. East Afr J Public Health. 2010;7(4):295-299.
227. Lissouba P, Taljaard D, Rech D, et al. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS Med. 2010;7(7):e1000309.
228. Young MR, Bailey RC, Odoyo-June E, et al. Safety of over twelve hundred infant male circumcisions using the Mogen clamp in Kenya. PLoS One. 2012;7(10):e47395.
229. Ford N, Chu K, Mills EJ. Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis. AIDS. 2012;26(5):559-566.
230. Justman J, Goldberg A, Reed J, Bock N, Njeuhmeli E, Goldzier Thomas A. Adult male circumcision: reflections on successes and challenges. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S140-S143.
231. Sánchez J, Sal Y Rosas VG, Hughes JP, et al. Male circumcision and risk of HIV acquisition among MSM. AIDS. 2011;25(4):519-523.
232. Hughes JP, Baeten JM, Lingappa JR, et al Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205(3):358-365.
233. Jin F, Prestage GP, Imrie J, et al. Anal sexually transmitted infections and risk of HIV infection in homosexual men. J Acquir Immune Defic Syndr. 2010;53(1):144-149.
234. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1-10.
235. Wandeler G, Gsponer T, Bregenzer A, et al Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55(10):1408-1416.
236. Centers for Disease Control (CDC) Division of STD Prevention. Sexually transmitted disease surveillance 2011. CDC website. http://www.cdc.gov/std/ stats11/Surv2011.pdf. Accessed December 2012. May 23, 2014.
237. Mayer KH, Bush T, Henry K, et al SUN Investigators. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis. 2012;39(1):1-7.
238. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis. 2013;56(10):1480- 1487.
239. Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men-STD Surveillance Network, United States, 2010-2012. Clin Infect Dis. 2014;58(11):1564-1570.
240. Hoover KW, Butler M, Workowski K, et al Evaluation Group for Adherence to STD and Hepatitis Screening. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis. 2010;37(12):771-776.
241. Centers for Disease Control and Prevention (CDC). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC website. http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5602a1.htm. Accessed May 23, 2014.
242. Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735-744.
243. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246-1253.
244. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS. 2013;27(4):493-505.
245. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptivemethods on HIV disease progression: a systematic review. AIDS. 2013;27(5):787-794.
246. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797-808.
247. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013;27(1):105-113.
248. Noguchi LM, Richardson B, Chirenje ZM, et al. Injectable contraception and HIV acquisition in the VOICE study (MTN-003) [CROI abstract 847]. Top Antivir Med. 2014;22(special issue e-1):441.
249. World Health Organization (WHO) Department of Reproductive Health and Research. Hormonal Contraception and HIV: Technical Statment. WHO website. http://whqlibdoc.who.int/hq/2012/WHO-RHR-12.08-eng.pdf. February 16, 2012. Accessed May 23, 2014.
250. Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep. 2012;61(24):449-452.